A new hemagglutination method for detection of unexpected antibodies

Information

  • Research Project
  • 8393355
  • ApplicationId
    8393355
  • Core Project Number
    R43HL112444
  • Full Project Number
    1R43HL112444-01A1
  • Serial Number
    112444
  • FOA Number
    PA-11-096
  • Sub Project Id
  • Project Start Date
    9/1/2012 - 13 years ago
  • Project End Date
    8/31/2014 - 11 years ago
  • Program Officer Name
    MITCHELL, PHYLLIS
  • Budget Start Date
    9/1/2012 - 13 years ago
  • Budget End Date
    8/31/2014 - 11 years ago
  • Fiscal Year
    2012
  • Support Year
    01
  • Suffix
    A1
  • Award Notice Date
    8/28/2012 - 13 years ago

A new hemagglutination method for detection of unexpected antibodies

DESCRIPTION (provided by applicant): The long-term goal of the proposed research is to develop a novel quantitative particle agglutination technology for improving the performance of assays for detection of allo-antibodies to red blood cell antigens. The conventional hemagglutination blood typing assays have serious drawbacks such as limited sensitivity, long time of incubation, subjectivity and large amount of reagents. It is in this context that we propos to develop a new technology, which is free from the aforementioned limitations of the conventional hemagglutination assays. The proposed immunoassay is a sensitive and rapid method that utilizes inexpensive instrumentation. Significantly, the method presents a general approach for enhancement and detection of agglutination of particles of different origin, including latex, silica microparticles, and biological cells. PUBLIC HEALTH RELEVANCE: The development of this method will allow one to obtain quantitative results, increase the sensitivity of particle and red cell agglutination assays, and reduce time of analysis without compromising the cost per test. Successful completion of these studies will make available all of the technology needed for a substantial business opportunity to license the technology and manufacture commercial products.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    148988
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:148988\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ALLIED INNOVATIVE SYSTEMS, LLC
  • Organization Department
  • Organization DUNS
    139604156
  • Organization City
    HILLSBOROUGH
  • Organization State
    NJ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    088441936
  • Organization District
    UNITED STATES